RLRichard T. Lee

Richard T. Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard T. Lee has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Peter Libby

    From the Leducq Center for Cardiovascular Research, Cardiovascular Division (M.L.L., J.Y., C.M., S.M., J.G., A.V., M.A., P.L., R.T.L.), Department of Medicine, Brigham and Women’s Hospital, and the Department of Medicine, Massachusetts General Hospital (S.M.K.), Harvard Medical School, Boston, Mass

    7 shared publications
  • Roger D. Kamm

    Division of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; and

    6 shared publications
  • Catherine MacGillivray

    5 shared publications
  • Patrick Ching-Ho Hsieh

    Institute of Biomedical Sciences, Academia Sinica

    5 shared publications
  • Ellen O. Weinberg

    Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, MA, USA

    4 shared publications
  • Hayden Huang

    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139; and †Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, MA 02139

    4 shared publications

Latest Publications

  • Salvianolic acid B–vitamin C synergy in cardiac differentiation from embryonic stem cells

    by Sunny Sun-Kin Chan, Jyh-Hong Chen, Shiaw-Min Hwang, I-Ju Wang, Hui-Jing Li, Richard T. Lee, Patrick C.H. Hsieh


  • Physical and Mechanical Stress

    by Luis E Rohde, Richard T Lee

  • Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction

    by Michael E. Davis, Patrick C. H. Hsieh, Tomosaburo Takahashi, Qing Song, Shuguang Zhang, Roger D. Kamm, Alan J. Grodzinsky, Piero Anversa, Richard T. Lee

    Strategies for cardiac repair include injection of cells, but these approaches have been hampered by poor cell engraftment, survival, and differentiation. To address these shortcomings for the purpose of improving cardiac function after injury, we designed self-assembling peptide nanofibers for prolonged delivery of insulin-like growth factor 1 (IGF-1), a cardiomyocyte growth and differentiation factor, to the myocardium, using a “biotin sandwich” approach. Biotinylated IGF-1 was complexed with tetravalent streptavidin and then bound to biotinylated self-assembling peptides. This biotin sandwich strategy allowed binding of IGF-1 but did not prevent self-assembly of the peptides into nanofibers within the myocardium. IGF-1 that was bound to peptide nanofibers activated Akt, decreased activation of caspase-3, and increased expression of cardiac troponin I in cardiomyocytes. After injection into rat myocardium, biotinylated nanofibers provided sustained IGF-1 delivery for 28 days, and targeted delivery of IGF-1 in vivo increased activation of Akt in the myocardium. When combined with transplanted cardiomyocytes, IGF-1 delivery by biotinylated nanofibers decreased caspase-3 cleavage by 28% and increased the myocyte cross-sectional area by 25% compared with cells embedded within nanofibers alone or with untethered IGF-1. Finally, cell therapy with IGF-1 delivery by biotinylated nanofibers improved systolic function after experimental myocardial infarction, demonstrating how engineering the local cellular microenvironment can improve cell therapy.


  • Open Access

    Three‐Dimensional Reconstruction of Tissues

    by Francisco Cruz, Richard T. Lee, Hayden Huang

    Cellular morphology is inherently three-dimensional. However, most histological techniques for tissue analysis focus on extracting information from two-dimensional slices of fixed samples or dissociated cells. These techniques result in a significant loss of the three-dimensional information of the tissue, including true cell volume, orientation, and whole cell shape. This unit discusses various options for three-dimensional imaging, provides a protocol for performing post-processing reconstruction based on serial slicing, and discusses the current advantages and limitations of the three-dimensional approach to quantitative tissue analysis. The focus of this protocol is on cardiac tissue, but the techniques can be applied to any solid tissue.

  • ENDOTHELIAL-CARDIOMYOCYTE INTERACTIONS IN CARDIAC DEVELOPMENT AND REPAIR

    by Patrick C.H. Hsieh, Michael E. Davis, Laura K. Lisowski, Richard T. Lee

    ▪ Abstract Communication between endothelial cells and cardiomyocytes regulates not only early cardiac development but also adult cardiomyocyte function, including the contractile state. In the normal mammalian myocardium, each cardiomyocyte is surrounded by an intricate network of capillaries and is next to endothelial cells. Cardiomyocytes depend on endothelial cells not only for oxygenated blood supply but also for local protective signals that promote cardiomyocyte organization and survival. While endothelial cells direct cardiomyocytes, cardiomyocytes reciprocally secrete factors that impact endothelial cell function. Understanding how endothelial cells communicate with cardiomyocytes will be critical for cardiac regeneration, in which the ultimate goal is not simply to improve systolic function transiently but to establish new myocardium that is both structurally and functionally normal in the long term.


  • Open Access

    Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers

    by Patrick C.H. Hsieh, Michael E. Davis, Joseph Gannon, Catherine MacGillivray, Richard T. Lee

    Endothelial cells can protect cardiomyocytes from injury, but the mechanism of this protection is incompletely described. Here we demonstrate that protection of cardiomyocytes by endothelial cells occurs through PDGF-BB signaling. PDGF-BB induced cardiomyocyte Akt phosphorylation in a time- and dose-dependent manner and prevented apoptosis via PI3K/Akt signaling. Using injectable self-assembling peptide nanofibers, which bound PDGF-BB in vitro, sustained delivery of PDGF-BB to the myocardium at the injected sites for 14 days was achieved. A blinded and randomized study in 96 rats showed that injecting nanofibers with PDGF-BB, but not nanofibers or PDGF-BB alone, decreased cardiomyocyte death and preserved systolic function after myocardial infarction. A separate blinded and randomized study in 52 rats showed that PDGF-BB delivered with nanofibers decreased infarct size after ischemia/reperfusion. PDGF-BB with nanofibers induced PDGFR-β and Akt phosphorylation in cardiomyocytes in vivo. These data demonstrate that endothelial cells protect cardiomyocytes via PDGF-BB signaling and that this in vitro finding can be translated into an effective in vivo method of protecting myocardium after infarction. Furthermore, this study shows that injectable nanofibers allow precise and sustained delivery of proteins to the myocardium with potential therapeutic benefits.


  • Open Access

    Cardiomyocyte hypertrophy and degradation of connexin43 through spatially restricted autocrine/paracrine heparin-binding EGF

    by Jun Yoshioka, Robin N. Prince, Hayden Huang, Scott B. Perkins, Francisco U. Cruz, Catherine MacGillivray, Douglas A. Lauffenburger, Richard T. Lee

    Growth factor signaling can affect tissue remodeling through autocrine/paracrine mechanisms. Recent evidence indicates that EGF receptor transactivation by heparin-binding EGF (HB-EGF) contributes to hypertrophic signaling in cardiomyocytes. Here, we show that HB-EGF operates in a spatially restricted circuit in the extracellular space within the myocardium, revealing the critical nature of the local microenvironment in intercellular signaling. This highly localized microenvironment of HB-EGF signaling was demonstrated with 3D morphology, consistent with predictions from a computational model of EGF signaling. HB-EGF secretion by a given cardiomyocyte in mouse left ventricles led to cellular hypertrophy and reduced expression of connexin43 in the overexpressing cell and in immediately adjacent cells but not in cells farther away. Thus, HB-EGF acts as an autocrine and local paracrine cardiac growth factor that leads to loss of gap junction proteins within a spatially confined microenvironment. These findings demonstrate how cells can coordinate remodeling with their immediate neighboring cells with highly localized extracellular EGF signaling.


  • Custom Design of the Cardiac Microenvironment With Biomaterials

    by Michael E. Davis, Patrick C.H. Hsieh, Alan J. Grodzinsky, Richard T. Lee

    Many strategies for repairing injured myocardium are under active investigation, with some early encouraging results. These strategies include cell therapies, despite little evidence of long-term survival of exogenous cells, and gene or protein therapies, often with incomplete control of locally-delivered dose of the factor. We propose that, ultimately, successful repair and regeneration strategies will require quantitative control of the myocardial microenvironment. This precision control can be engineered through designed biomaterials that provide quantitative adhesion, growth, or migration signals. Quantitative timed release of factors can be regulated by chemical design to direct cellular differentiation pathways such as angiogenesis and vascular maturation. Smart biomaterials respond to the local environment, such as protease activity or mechanical forces, with controlled release or activation. Most of these new biomaterials provide much greater flexibility for regenerating tissues ex vivo, but emerging technologies like self-assembling nanofibers can now establish intramyocardial cellular microenvironments by injection. This may allow percutaneous cardiac regeneration and repair approaches, or injectable-tissue engineering. Finally, materials can be made to multifunction by providing sequential signals with custom design of differential release kinetics for individual factors. Thus, new rationally-designed biomaterials no longer simply coexist with tissues, but can provide precision bioactive control of the microenvironment that may be required for cardiac regeneration and repair.


  • Open Access

    Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion

    by Ellen O. Weinberg, Marielle Scherrer-Crosbie, Michael H. Picard, Boris A. Nasseri, Catherine MacGillivray, Joseph Gannon, Qingyu Lian, Kenneth D. Bloch, Richard T. Lee

    This study compared the effects of rosuvastatin on left ventricular infarct size in mice after permanent coronary occlusion vs. 60 min of ischemia followed by 24 h of reperfusion. Statins can inhibit neutrophil adhesion, increase nitric oxide synthase (NOS) expression, and mobilize progenitor stem cells after ischemic injury. Mice received blinded and randomized administration of rosuvastatin (20 mg·kg−1·day−1) or saline from 2 days before surgery until death. After 60 min of ischemia with reperfusion, infarct size was reduced by 18% ( P = 0.03) in mice randomized to receive rosuvastatin ( n = 18) vs. saline ( n = 22) but was similar after permanent occlusion in rosuvastatin ( n = 17) and saline ( n = 20) groups ( P = not significant). Myocardial infarct size after permanent left anterior descending coronary artery occlusion ( n = 6) tended to be greater in NOS3-deficient mice than in the wild-type saline group (33 ± 4 vs. 23 ± 2%, P = 0.08). Infarct size in NOS3-deficient mice was not modified by treatment with rosuvastatin (34 ± 5%, n = 6, P = not significant vs. NOS3-deficient saline group). After 60 min of ischemia-reperfusion, neutrophil infiltration was similar in rosuvastatin and saline groups as was the percentage of CD34+, Sca-1+, and c-Kit+ cells. Left ventricular NOS3 mRNA and protein levels were unchanged by rosuvastatin. Rosuvastatin reduces infarct size after 60 min of ischemia-reperfusion but not after permanent coronary occlusion, suggesting a potential anti-inflammatory effect. Although we were unable to demonstrate that the myocardial protection was due to an effect on neutrophil infiltration, stem cell mobilization, or induction of NOS3, these data suggest that rosuvastatin may be particularly beneficial in myocardial protection after ischemia-reperfusion injury.


  • Macrophage-Mediated Cardiac Fibrosis

    by P. Christian Schulze, Richard T. Lee

    Oth clinicians and investigators have long tended to consider cardiac fibrosis as a hopelessly unavoidable "final common pathway" of tissue injury. We are painfully familiar with the serious consequences of myocar- dial fibrosis, including diastolic dysfunction and promoting reentry dysrhythmias,1 but we seem to accept that diseased myocardium eventually develops fibrosis. However, only the most advanced fibrotic tissues are lifeless; in fact, dynamic matrix turnover in fibrosing tissues is easily demonstrated, whereas the matrix of normal tissues is, in comparison, remarkably quiescent. That we can potentially steer matrix metabolism beneficially to reduce dysrhythmias or improve ventricular function is reason enough to try to understand cardiac fibrosis. In addition, as we will briefly touch on here, recent excitement in cardiac regeneration offers us yet an- other important reason to unravel fibrosis, because myocar- dial scarring may be standing in the way of successfully repairing the heart. Treatment options to prevent cardiac fibrosis are limited and include angiotensin converting enzyme inhibitors2 and aldosterone blockade.3 Matrix metalloproteinase inhibition may also reduce fibrosis.4,5 The effects of metalloproteinase inhibition on cardiac fibrosis do not appear to be attributable to changes in collagen degradation, and there has been little recent progress on using metalloproteinase inhibition clini- cally. With so few weapons against cardiac fibrosis, it is therefore important to develop new strategies through under- standing basic molecular pathways of matrix metabolism. There are different types of cardiac fibrosis, and some forms of fibrosis are probably at least transiently beneficial. The fibrosis of the healing infarct in the days after myocardial infarction prevents cardiac rupture, but eventually dense regions of fibrosis may be arrhythmogenic. Pressure over- loaded myocardium causes fibrosis within weeks that is initially perivascular 1; this is so reproducible that sham-